N
NGM Biopharmaceuticals
Biotech & Life Sciences · South San Francisco, United States · Founded 2007 · IPO 2019
A clinical-stage biopharmaceutical company which engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases MoreLess
NGM Bio is a biopharmaceutical company dedicated to discovering and developing novel medicines aimed at transforming the lives of patients affected by serious diseases. The company employs a biology-centric drug discovery approach, integrating complex disease biology with protein engineering to generate proprietary insights. These insights are used to create promising product candidates that can quickly advance into proof-of-concept studies. NGM Bio's research and development engine is highly productive, with all therapeutic candidates in its pipeline originating from its in-house discovery efforts. The company serves patients with unmet medical needs and operates in the biopharmaceutical market. NGM Bio's business model focuses on leveraging its scientific expertise to develop and commercialize new therapies, thereby generating revenue through the successful advancement and eventual market introduction of its drug candidates. Currently, the company has four programs in active clinical development, supported by a strong financial position and a healthy cash runway. Keywords: biopharmaceutical, drug discovery, protein engineering, disease biology, patient needs, clinical development, research, development, medicines, therapeutic candidates.
Talent graph
NGM Biopharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Investors
7 investors on NGM Biopharmaceuticals's cap table
Sourced from Dealroom's funding history.






Global footprint
Where NGM Biopharmaceuticals has talent and traffic
team presence
across markets
Patent intelligence
$86M patent portfolio · 41 active families
Where NGM Biopharmaceuticals concentrates vs peers
Each axis is a top-10 topic across NGM Biopharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Market sentiment
What the market is saying about NGM Biopharmaceuticals
An AI-synthesized read of the highest-engagement posts about NGM Biopharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NGM Biopharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.